Asuragen’s Signature NPM1 Mutations is said to be a sensitive molecular assay for the combined detection of mutations A, B and D in exon 12 of the nucleophosmin (NPM1) gene. Asuragen is one of two exclusive licensees to NPM1.
The assay is performed on the Luminex 100 IS or 200 System using a liquid bead array method. Accoring to the company, the liquid bead array format provides comprehensive information in a single well, providing efficiency and cost benefits to the laboratory.
Signature NPM1 Mutations can be used for the rapid detection and identification of mutations in NPM1. The assay is said to be designed to detect NPM1 mutant transcripts in total RNA isolated from cell line, whole blood and bone marrow specimens. NPM1 has been reported to be one of the most commonly mutated genes in acute myeloid leukemia (AML).
Timothy Stenzel, Asuragen’s chief medical officer, said: “This assay should prove highly useful to AML researchers wishing to investigate the potential clinical role for NPM1 mutation detection.”